Novartis Files Third Patent Suit Over Generic Lotrel

Law360, New York (October 11, 2006, 12:00 AM EDT) -- Novartis Corp. has stuck Par Pharmaceuticals with a patent infringement lawsuit over the hypertension drug Lotrel, marking the third suit Novartis has brought against a generic pharmaceutical company that has asserted the Lotrel patent is invalid.

On August 31, 2006, Novartis received a letter from Par stating that Par had filed an abbreviated new drug application for a drug that relies on the patent Novartis uses for Lotrel, according to the lawsuit.

The ANDA stated that Novartis’ patent is invalid and unenforceable, and therefore Par’s new...
To view the full article, register now.